Literature DB >> 7635562

Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition?

P Bonnier1, C Charpin, C Lejeune, S Romain, N Tubiana, B Beedassy, P M Martin, H Serment, L Piana.   

Abstract

Some controversy remains about the clinical or pathological definition of the different types of inflammatory breast cancer (IBC) and especially the diagnostic and prognostic value of dermal lymphatic involvement. Our purpose was to classify the different types of IBC for which diagnosis was confirmed intraoperatively and ascertain features allowing reliable diagnosis. We studied clinical findings, biological data, and treatment outcome in a series of 144 successive patients. Our results suggest that there are 2 biologically different entities i.e., true IBC and pseudo-IBC. True IBC, whose course is currently fatal in all cases, can be divided into 2 sub-categories i.e., common true IBC (75.7% of cases), in which inflammatory signs occur primarily or secondarily, and occult true IBC (13.2% of cases). Dermal emboli have been observed in 61% of common true IBC, but their absence did not alter the rapidly unfavourable outcome. Extensive lymph-node involvement, other biological features and survival were the same in the 2 sub-categories. Pseudo-IBC (11.1% of cases) can easily be confused with common true IBC. The biological characteristics of pseudo-IBC differ from those of true IBC: no dermal lymphatic involvement and little or no lymph-node involvement. Despite large tumour size, outcome was particularly favourable. It is of great importance to differentiate true and pseudo-IBC, for which the treatments are different. Confirmation of true IBC requires pathological demonstration of dermal lymphatic emboli or extensive lymph-node involvement. Occult IBC must be identified for patients presenting rapidly growing tumours.

Entities:  

Mesh:

Year:  1995        PMID: 7635562     DOI: 10.1002/ijc.2910620404

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  35 in total

Review 1.  Inflammatory breast cancer: what we know and what we need to learn.

Authors:  Hideko Yamauchi; Wendy A Woodward; Vicente Valero; Ricardo H Alvarez; Anthony Lucci; Thomas A Buchholz; Takayuki Iwamoto; Savitri Krishnamurthy; Wei Yang; James M Reuben; Gabriel N Hortobágyi; Naoto T Ueno
Journal:  Oncologist       Date:  2012-05-14

2.  Inflammatory breast cancer: the experience of Baylor University Medical Center at Dallas.

Authors:  Justin M Goldfarb; John E Pippen
Journal:  Proc (Bayl Univ Med Cent)       Date:  2011-04

3.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.

Authors:  Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine
Journal:  J Natl Cancer Inst       Date:  2005-07-06       Impact factor: 13.506

4.  Authors' reply: Inflammatory breast cancer: a clinical diagnosis.

Authors:  Sadaf Alipour; Akram Seifollahi; Robab Anbiaee
Journal:  Singapore Med J       Date:  2014-03       Impact factor: 1.858

5.  How do I treat inflammatory breast cancer?

Authors:  Della Makower; Joseph A Sparano
Journal:  Curr Treat Options Oncol       Date:  2013-03

6.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

Authors:  S Dawood; S D Merajver; P Viens; P B Vermeulen; S M Swain; T A Buchholz; L Y Dirix; P H Levine; A Lucci; S Krishnamurthy; F M Robertson; W A Woodward; W T Yang; N T Ueno; M Cristofanilli
Journal:  Ann Oncol       Date:  2010-07-05       Impact factor: 32.976

7.  Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties.

Authors:  Mona M Mohamed; Eslam A El-Ghonaimy; Mohamed A Nouh; Robert J Schneider; Bonnie F Sloane; Mohamed El-Shinawi
Journal:  Int J Biochem Cell Biol       Date:  2013-11-26       Impact factor: 5.085

8.  Incidence of inflammatory breast cancer in women, 1992-2009, United States.

Authors:  Bryan Goldner; Carolyn E Behrendt; Hans F Schoellhammer; Byrne Lee; Steven L Chen
Journal:  Ann Surg Oncol       Date:  2013-12-24       Impact factor: 5.344

9.  Inflammatory breast cancer in a previously treated case of breast cancer: a diagnostic dilemma for the clinician.

Authors:  Rahul Ravind; Priyadarshini Venkatram Kumar; Sasikala Prabaharan
Journal:  BMJ Case Rep       Date:  2016-04-08

10.  Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer.

Authors:  Ryan A Denu; John M Hampton; Adam Currey; Roger T Anderson; Rosemary D Cress; Steven T Fleming; Joseph Lipscomb; Susan A Sabatino; Xiao-Cheng Wu; J Frank Wilson; Amy Trentham-Dietz
Journal:  Cancer Epidemiol       Date:  2015-11-21       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.